Intravascular hemolysis and the pathophysiology of sickle cell disease

Journal of Clinical Investigation

Volumn 127, Issue 3, 2017, Pages 750-760

  Kato, Gregory J ^a   Steinberg, Martin H ^b   Gladwin, Mark T ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE NUCLEOTIDE; ALANINE AMINOTRANSFERASE; ARGINASE 1; HAPTOGLOBIN; HEMOGLOBIN; HEMOSIDERIN; LACTATE DEHYDROGENASE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; METHEMOGLOBIN;

ALPHA THALASSEMIA; ANGIOGENESIS; BLOOD FLOW; BLOOD VISCOSITY; BRAIN ISCHEMIA; CHRONIC KIDNEY FAILURE; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; HEMATOCRIT; HEMOSTASIS; INFLAMMATION; INNATE IMMUNITY; INTRAVASCULAR HEMOLYSIS; LEG ULCER; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PH; PREVALENCE; PRIAPISM; PROTEINURIA; PULMONARY HYPERTENSION; REVIEW; SICKLE CELL ANEMIA; VASCULAR DISEASE; VASOCONSTRICTION; ADRENERGIC SYSTEM; BLOOD; HEMOLYSIS; HUMAN; METABOLISM;

ANEMIA, SICKLE CELL; HEMOLYSIS; HUMANS; METHEMOGLOBIN; NITRIC OXIDE; VASCULAR DISEASES; VASOMOTOR SYSTEM;

EID: 85015958869     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI89741     Document Type: Review

References (190)

1. van Beers EJ, et al. Imaging flow cytometry for automated detection of hypoxia-induced erythrocyte shape change in sickle cell disease. Am J Hematol. 2014;89(6):598-603.
2. Serjeant GR, Serjeant BE, Mason K. Heterocellular hereditary persistence of fetal haemoglobin and homozygous sickle-cell disease. Lancet. 1977;1(8015):795-796.
3. Noguchi CT, Torchia DA, Schechter AN. Intracellular polymerization of sickle hemoglobin. Effects of cell heterogeneity. J Clin Invest. 1983;72(3):846-852.
4. Fabry ME, Nagel RL. Heterogeneity of red cells in the sickler: a characteristic with practical clinical and pathophysiological implications. Blood Cells. 1982;8(1):9-15.
5. Platt OS, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991;325(1):11-16.
6. Barabino GA, Platt MO, Kaul DK. Sickle cell biomechanics. Annu Rev Biomed Eng. 2010;12:345-367.
7. Telen MJ. Cellular adhesion and the endothelium: E-selectin, L-selectin, and pan-selectin inhibitors. Hematol Oncol Clin North Am. 2014;28(2):341-354.
8. Kutlar A, Embury SH. Cellular adhesion and the endothelium: P-selectin. Hematol Oncol Clin North Am. 2014;28(2):323-339.
9. Zhang D, Xu C, Manwani D, Frenette PS. Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood. 2016;127(7):801-809.
10. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007;21(1):37-47.
11. Hebbel RP. Reconstructing sickle cell disease: a data-based analysis of the hyperhemolysis paradigm for pulmonary hypertension from the perspective of evidence-based medicine. Am J Hematol. 2011;86(2):123-154.
12. Bunn HF, et al. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood. 2010;116(5):687-692.
13. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293(13):1653-1662.
14. Doyle MP, Hoekstra JW. Oxidation of nitrogen oxides by bound dioxygen in hemoproteins. J Inorg Biochem. 1981;14(4):351-358.
15. Alayash AI, Cashon RE. Hemoglobin and free radicals: implications for the development of a safe blood substitute. Mol Med Today. 1995;1(3):122-127.
16. Reiter CD, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8(12):1383-1389.
17. Morris CR, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA. 2005;294(1):81-90.
18. Landburg PP, et al. Plasma asymmetric dimethylarginine concentrations in sickle cell disease are related to the hemolytic phenotype. Blood Cells Mol Dis. 2010;44(4):229-232.
19. Gladwin MT, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350(9):886-895.
20. Kato GJ, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood. 2006;107(6):2279-2285.
21. Gramaglia I, et al. Low nitric oxide bioavailability contributes to the genesis of experimental cerebral malaria. Nat Med. 2006;12(12):1417-1422.
22. Baldwin C, et al. Association of klotho, bone morphogenic protein 6, and annexin A2 polymorphisms with sickle cell osteonecrosis. Blood. 2005;106(1):372-375.
23. Bernaudin F, et al. G6PD deficiency, absence of alpha-thalassemia, and hemolytic rate at baseline are significant independent risk factors for abnormally high cerebral velocities in patients with sickle cell anemia. Blood. 2008;112(10):4314-4317.
24. Day TG, Drasar ER, Fulford T, Sharpe CC, Thein SL. Association between hemolysis and albuminuria in adults with sickle cell anemia. Haematologica. 2012;97(2):201-205.
25. Milton JN, et al. Genetic determinants of haemolysis in sickle cell anaemia. Br J Haematol. 2013;161(2):270-278.
26. Hamideh D, et al. Albuminuria correlates with hemolysis and NAG and KIM-1 in patients with sickle cell anemia. Pediatr Nephrol. 2014;29(10):1997-2003.
27. Miller ST, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med. 2000;342(2):83-89.
28. Quinn CT, Lee NJ, Shull EP, Ahmad N, Rogers ZR, Buchanan GR. Prediction of adverse outcomes in children with sickle cell anemia: a study of the Dallas Newborn Cohort. Blood. 2008;111(2):544-548.
29. Baum KF, Dunn DT, Maude GH, Serjeant GR. The painful crisis of homozygous sickle cell disease. A study of the risk factors. Arch Intern Med. 1987;147(7):1231-1234.
30. Akinsheye I, et al. Fetal hemoglobin in sickle cell anemia. Blood. 2011;118(1):19-27.
31. Castro O, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood. 1994;84(2):643-649.
32. Bailey K, Morris JS, Thomas P, Serjeant GR. Fetal haemoglobin and early manifestations of homozygous sickle cell disease. Arch Dis Child. 1992;67(4):517-520.
33. Steinberg MH, Chui DH, Dover GJ, Sebastiani P, Alsultan A. Fetal hemoglobin in sickle cell anemia: a glass half full? Blood. 2014;123(4):481-485.
34. Franco RS, Yasin Z, Palascak MB, Ciraolo P, Joiner CH, Rucknagel DL. The effect of fetal hemoglobin on the survival characteristics of sickle cells. Blood. 2006;108(3):1073-1076.
35. De Ceulaer K, Higgs DR, Weatherall DJ, Hayes RJ, Serjeant BE, Serjeant GR. Thalassemia reduces the hemolytic rate in homozygous sickle-cell disease [letter]. N Engl J Med. 1983;309(3):189-190.
36. Steinberg MH, Sebastiani P. Genetic modifiers of sickle cell disease. Am J Hematol. 2012;87(8):795-803.
37. Ataga KI, et al. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043). Br J Haematol. 2011;153(1):92-104.
38. Minniti CP, et al. Anti-haemolytic effect of senicapoc and decrease in NT-proBNP in adults with sickle cell anaemia. Br J Haematol. 2011;155(5):634-636.
39. Machado RF, et al. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA. 2006;296(3):310-318.
40. Embury SH, Clark MR, Monroy G, Mohandas N. Concurrent sickle cell anemia and thalassemia. Effect on pathological properties of sickle erythrocytes. J Clin Invest. 1984;73(1):116-123.
41. Ballas SK, Marcolina MJ. Hyperhemolysis during the evolution of uncomplicated acute painful episodes in patients with sickle cell anemia. Transfusion. 2006;46(1):105-110.
42. Taylor JG, Nolan VG, Mendelsohn L, Kato GJ, Gladwin MT, Steinberg MH. Chronic hyper-hemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive pain. PLoS One. 2008;3(5):e2095.
43. Guasch A, Zayas CF, Eckman JR, Muralidharan K, Zhang W, Elsas LJ. Evidence that microdeletions in the alpha globin gene protect against the development of sickle cell glomerulopathy in humans. J Am Soc Nephrol. 1999;10(5):1014-1019.
44. Liem RI, Young LT, Thompson AA. Tricuspid regurgitant jet velocity is associated with hemolysis in children and young adults with sickle cell disease evaluated for pulmonary hypertension. Haematologica. 2007;92(11):1549-1552.
45. Saraf SL, et al. Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia. Br J Haematol. 2014;164(5):729-739.
46. Minniti CP, et al. Laboratory and echocardiography markers in sickle cell patients with leg ulcers. Am J Hematol. 2011;86(8):705-708.
47. Caughey MC, Poole C, Ataga KI, Hinderliter AL. Estimated pulmonary artery systolic pressure and sickle cell disease: a meta-analysis and systematic review. Br J Haematol. 2015;170(3):416-424.
48. Ataga KI, et al. Pulmonary hypertension in sickle cell disease. Am J Med. 2004;117(9):665-669.
49. Ataga KI, et al. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol. 2006;134(1):109-115.
50. Naoman SG, et al. Echocardiographic findings in patients with sickle cell disease. Ann Hematol. 2010;89(1):61-66.
51. Gladwin MT, et al. Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom. PLoS One. 2014;9(7):e99489.
52. Onyekwere OC, et al. Pulmonary hypertension in children and adolescents with sickle cell disease. Pediatr Cardiol. 2008;29(2):309-312.
53. van Beers EJ, et al. Cardiopulmonary imaging, functional and laboratory studies in sickle cell disease associated pulmonary hypertension. Am J Hematol. 2008;83(11):850-854.
54. Machado RF, Hildesheim M, Mendelsohn L, Remaley AT, Kato GJ, Gladwin MT. NT-pro brain natriuretic peptide levels and the risk of death in the cooperative study of sickle cell disease. Br J Haematol. 2011;154(4):512-520.
55. Caughey MC, Hinderliter AL, Jones SK, Shah SP, Ataga KI. Hemodynamic characteristics and predictors of pulmonary hypertension in patients with sickle cell disease. Am J Cardiol. 2012;109(9):1353-1357.
56. Lee MT, Rosenzweig EB, Cairo MS. Pulmonary hypertension in sickle cell disease. Clin Adv Hematol Oncol. 2007;5(8):645-653.
57. Derchi G, et al. Prevalence and risk factors for pulmonary arterial hypertension in a large group of thalassemia patients using right heart catheterization: a Webthal study. Circulation. 2014;129(3):338-345.
58. Naik RP, Streiff MB, Haywood C Jr. Nelson JA, Lanzkron S. Venous thromboembolism in adults with sickle cell disease: a serious and under-recognized complication. Am J Med. 2013;126(5):443-449.
59. Cappellini MD, Musallam KM, Taher AT. Insight onto the pathophysiology and clinical complications of thalassemia intermedia. Hemoglobin. 2009;33(suppl 1):S145-S159.
60. De Castro LM, Jonassaint JC, Graham FL, Ashley-Koch A, Telen MJ. Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. Am J Hematol. 2008;83(1):19-25.
61. Minniti CP, et al. Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation. Haematologica. 2009;94(3):340-347.
62. Voskaridou E, Tsetsos G, Tsoutsias A, Spyropoulou E, Christoulas D, Terpos E. Pulmonary hypertension in patients with sickle cell/beta thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations. Haematologica. 2007;92(6):738-743.
63. Damy T, et al. Haematological determinants of cardiac involvement in adults with sickle cell disease. Eur Heart J. 2016;37(14):1158-1167.
64. Mehari A, et al. Hemodynamic predictors of mortality in adults with sickle cell disease. Am J Respir Crit Care Med. 2013;187(8):840-847.
65. Parent F, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med. 2011;365(1):44-53.
66. Fonseca GH, Souza R, Salemi VM, Jardim CV, Gualandro SF. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. Eur Respir J. 2012;39(1):112-118.
67. Niss O, et al. Cardiomyopathy with restrictive physiology in sickle cell disease. JACC Cardiovasc Imaging. 2016;9(3):243-252.
68. Sachdev V, et al. Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United Kingdom. Circulation. 2011;124(13):1452-1460.
69. Johnson MC, et al. Left ventricular hypertrophy and diastolic dysfunction in children with sickle cell disease are related to asleep and waking oxygen desaturation. Blood. 2010;116(1):16-21.
70. Dham N, et al. Prospective echocardiography assessment of pulmonary hypertension and its potential etiologies in children with sickle cell disease. Am J Cardiol. 2009;104(5):713-720.
71. Nolan VG, Wyszynski DF, Farrer LA, Steinberg MH. Hemolysis-associated priapism in sickle cell disease. Blood. 2005;106(9):3264-3267.
72. Lorch D, Spevack D, Little J. An elevated estimated pulmonary arterial systolic pressure, whenever measured, is associated with excess mortality in adults with sickle cell disease. Acta Haematol. 2011;125(4):225-229.
73. Forrest S, Kim A, Carbonella J, Pashankar F. Proteinuria is associated with elevated tricuspid regurgitant jet velocity in children with sickle cell disease. Pediatr Blood Cancer. 2012;58(6):937-940.
74. Anthi A, et al. Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med. 2007;175(12):1272-1279.
75. Gordeuk VR, et al. Elevated tricuspid regurgitation velocity and decline in exercise capacity over 22 months of follow up in children and adolescents with sickle cell anemia. Haematologica. 2011;96(1):33-40.
76. Mehari A, Gladwin MT, Tian X, Machado RF, Kato GJ. Mortality in adults with sickle cell disease and pulmonary hypertension. JAMA. 2012;307(12):1254-1256.
77. D'Alonzo GE, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343-349.
78. Hsu LL, et al. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood. 2007;109(7):3088-3098.
79. Kaul DK, Liu XD, Chang HY, Nagel RL, Fabry ME. Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice. J Clin Invest. 2004;114(8):1136-1145.
80. Detterich JA, Kato RM, Rabai M, Meiselman HJ, Coates TD, Wood JC. Chronic transfusion therapy improves but does not normalize systemic and pulmonary vasculopathy in sickle cell disease. Blood. 2015;126(6):703-710.
81. Kaul DK, Liu XD, Fabry ME, Nagel RL. Impaired nitric oxide-mediated vasodilation in transgenic sickle mouse. Am J Physiol Heart Circ Physiol. 2000;278(6):H1799-H1806.
82. Hanson MS, et al. A novel hemoglobin-binding peptide reduces cell-free hemoglobin in murine hemolytic anemia. Am J Physiol Heart Circ Physiol. 2013;304(2):H328-H336.
83. Frei AC, et al. Vascular dysfunction in a murine model of severe hemolysis. Blood. 2008;112(2):398-405.
84. Vinchi F, et al. Hemopexin therapy improves cardiovascular function by preventing heme-induced endothelial toxicity in mouse models of hemolytic diseases. Circulation. 2013;127(12):1317-1329.
85. Hu W, et al. The critical roles of platelet activation and reduced NO bioavailability in fatal pulmonary arterial hypertension in a murine hemolysis model. Blood. 2010;116(9):1613-1622.
86. Minneci PC, et al. Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin. J Clin Invest. 2005;115(12):3409-3417.
87. Tofovic SP, Jackson EK, Rafikova O. Adenosine deaminase-adenosine pathway in hemolysisassociated pulmonary hypertension. Med Hypotheses. 2009;72(6):713-719.
88. Yu B, Raher MJ, Volpato GP, Bloch KD, Ichinose F, Zapol WM. Inhaled nitric oxide enables artificial blood transfusion without hypertension. Circulation. 2008;117(15):1982-1990.
89. Donadee C, et al. Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. Circulation. 2011;124(4):465-476.
90. Berra L, et al. Autologous transfusion of stored red blood cells increases pulmonary artery pressure. Am J Respir Crit Care Med. 2014;190(7):800-807.
91. Schaer CA, et al. Haptoglobin preserves vascular nitric oxide signaling during hemolysis. Am J Respir Crit Care Med. 2016;193(10):1111-1122.
92. Almeida CB, et al. Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea. Blood. 2015;126(6):711-720.
93. Yu B, Lei C, Baron DM, Steinbicker AU, Bloch KD, Zapol WM. Diabetes augments and inhaled nitric oxide prevents the adverse hemodynamic effects of transfusing syngeneic stored blood in mice. Transfusion. 2012;52(7):1410-1422.
94. Lei C, Yu B, Shahid M, Beloiartsev A, Bloch KD, Zapol WM. Inhaled nitric oxide attenuates the adverse effects of transfusing stored syngeneic erythrocytes in mice with endothelial dysfunction after hemorrhagic shock. Anesthesiology. 2012;117(6):1190-1202.
95. Risbano MG, et al. Effects of aged stored autologous red blood cells on human endothelial function. Am J Respir Crit Care Med. 2015;192(10):1223-1233.
96. Baek JH, et al. Hemoglobin-driven pathophysiology is an in vivo consequence of the red blood cell storage lesion that can be attenuated in guinea pigs by haptoglobin therapy. J Clin Invest. 2012;122(4):1444-1458.
97. Yeo TW, et al. Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria. J Exp Med. 2007;204(11):2693-2704.
98. Yeo TW, et al. Relationship of cell-free hemoglobin to impaired endothelial nitric oxide bioavailability and perfusion in severe falciparum malaria. J Infect Dis. 2009;200(10):1522-1529.
99. Janka JJ, et al. Increased pulmonary pressures and myocardial wall stress in children with severe malaria. J Infect Dis. 2010;202(5):791-800.
100. Vinchi F, Tolosano E. Therapeutic approaches to limit hemolysis-driven endothelial dysfunction: scavenging free heme to preserve vasculature homeostasis. Oxid Med Cell Longev. 2013;2013:396527.
101. Serghides L, et al. Inhaled nitric oxide reduces endothelial activation and parasite accumulation in the brain, and enhances survival in experimental cerebral malaria. PLoS One. 2011;6(11):e27714.
102. Soares MP, Bozza MT. Red alert: labile heme is an alarmin. Curr Opin Immunol. 2016;38:94-100.
103. Roumenina LT, Rayes J, Lacroix-Desmazes S, Dimitrov JD. Heme: Modulator of plasma systems in hemolytic diseases. Trends Mol Med. 2016;22(3):200-213.
104. Ghosh S, et al. Extracellular hemin crisis triggers acute chest syndrome in sickle mice. J Clin Invest. 2013;123(11):4809-4820.
105. Belcher JD, et al. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood. 2014;123(3):377-390.
106. Vercellotti GM, et al. Hepatic overexpression of hemopexin inhibits inflammation and vascular stasis in murine models of Sickle Cell disease. Mol Med. 2016;22:437-451.
107. Vinchi F, et al. Hemopexin therapy reverts heme-induced proinflammatory phenotypic switching of macrophages in a mouse model of sickle cell disease. Blood. 2016;127(4):473-486.
108. Sparkenbaugh EM, et al. Excess of heme induces tissue factor-dependent activation of coagulation in mice. Haematologica. 2015;100(3):308-314.
109. Chen G, Zhang D, Fuchs TA, Manwani D, Wagner DD, Frenette PS. Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease. Blood. 2014;123(24):3818-3827.
110. Wang X, et al. Heme-bound iron activates placenta growth factor in erythroid cells via erythroid Krüppel-like factor. Blood. 2014;124(6):946-954.
111. Sundaram N, et al. High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension. Blood. 2010;116(1):109-112.
112. Reiter CD, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8(12):1383-1389.
113. Wood KC, Granger DN. Sickle cell disease: role of reactive oxygen and nitrogen metabolites. Clin Exp Pharmacol Physiol. 2007;34(9):926-932.
114. Hebbel RP. The sickle erythrocyte in double jeopardy: autoxidation and iron decompartmentalization. Semin Hematol. 1990;27(1):51-69.
115. Aufradet E, et al. Hypoxia/reoxygenation stress increases markers of vaso-occlusive crisis in sickle SAD mice. Clin Hemorheol Microcirc. 2013;54(3):297-312.
116. Belcher JD, Beckman JD, Balla G, Balla J, Vercellotti G. Heme degradation and vascular injury. Antioxid Redox Signal. 2010;12(2):233-248.
117. Aslan M, Thornley-Brown D, Freeman BA. Reactive species in sickle cell disease. Ann N Y Acad Sci. 2000;899:375-391.
118. Repka T, Hebbel RP. Hydroxyl radical formation by sickle erythrocyte membranes: role of pathologic iron deposits and cytoplasmic reducing agents. Blood. 1991;78(10):2753-2758.
119. Reeder BJ. The redox activity of hemoglobins: from physiologic functions to pathologic mechanisms. Antioxid Redox Signal. 2010;13(7):1087-1123.
120. Cyrklaff M, et al. Hemoglobins S and C interfere with actin remodeling in Plasmodium falciparum-infected erythrocytes. Science. 2011;334(6060):1283-1286.
121. Kassa T, et al. Sickle Cell Hemoglobin in the ferryl state promotes Cys-93 oxidation and mitochondrial dysfunction in epithelial lung cells (E10). J Biol Chem. 2015;290(46):27939-27958.
122. Hebbel RP, Key NS. Microparticles in sickle cell anaemia: promise and pitfalls. Br J Haematol. 2016;174(1):16-29.
123. Camus SM, et al. Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease. Blood. 2015;125(24):3805-3814.
124. van Beers EJ, et al. Iron, inflammation, and early death in adults with sickle cell disease. Circ Res. 2015;116(2):298-306.
125. Dutra FF, et al. Hemolysis-induced lethality involves inflammasome activation by heme. Proc Natl Acad Sci U S A. 2014;111(39):E4110-E4118.
126. Gladwin MT, Ofori-Acquah SF. Erythroid DAMPs drive inflammation in SCD. Blood. 2014;123(24):3689-3690.
127. Mendonça R, Silveira AA, Conran N. Red cell DAMPs and inflammation. Inflamm Res. 2016;65(9):665-678.
128. Cardenes N, et al. Platelet bioenergetic screen in sickle cell patients reveals mitochondrial complex V inhibition, which contributes to platelet activation. Blood. 2014;123(18):2864-2872.
129. Kato GJ. TRV: a physiological biomarker in sickle cell disease. Pediatr Blood Cancer. 2012;58(6):831-832.
130. Upadhya B, Stacey RB, Ntim W, Knovich MA, Pu M. Echocardiography-derived tricuspid regurgitant jet velocity is an important marker for the progression of sickle-cell disease. Acta Haematol. 2014;132(2):152-158.
131. Nguyen KL, et al. Elevated transpulmonary gradient and cardiac magnetic resonancederived right ventricular remodeling predict poor outcomes in sickle cell disease. Haematologica. 2016;101(2):e40-e43.
132. Bakeer N, et al. Sickle cell anemia mice develop a unique cardiomyopathy with restrictive physiology. Proc Natl Acad Sci U S A. 2016;113(35):E5182-E5191.
133. Quinn CT, et al. Biochemical surrogate markers of hemolysis do not correlate with directly measured erythrocyte survival in sickle cell anemia. Am J Hematol. 2016;91(12):1195-1201.
134. Jison ML, et al. Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease. Blood. 2004;104(1):270-280.
135. Belcher JD, et al. Low-density lipoprotein susceptibility to oxidation and cytotoxicity to endothelium in sickle cell anemia. J Lab Clin Med. 1999;133(6):605-612.
136. Yuditskaya S, et al. Proteomic identification of altered apolipoprotein patterns in pulmonary hypertension and vasculopathy of sickle cell disease. Blood. 2009;113(5):1122-1128.
137. Zorca S, et al. Lipid levels in sickle-cell disease associated with haemolytic severity, vascular dysfunction and pulmonary hypertension. Br J Haematol. 2010;149(3):436-445.
138. Ataga KI, et al. Association of pro-inflammatory high-density lipoprotein cholesterol with clinical and laboratory variables in sickle cell disease. Hematology. 2015;20(5):289-296.
139. Nouraie M, et al. The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica. 2013;98(3):464-472.
140. Brittain JE, et al. Placenta growth factor in sickle cell disease: association with hemolysis and inflammation. Blood. 2010;115(10):2014-2020.
141. Ataga KI, et al. Albuminuria is associated with endothelial dysfunction and elevated plasma endothelin-1 in Sickle Cell anemia. PLoS One. 2016;11(9):e0162652.
142. Heimlich JB, et al. Endothelin-1 contributes to the progression of renal injury in sickle cell disease via reactive oxygen species. Br J Pharmacol. 2016;173(2):386-395.
143. Sabaa N, et al. Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. J Clin Invest. 2008;118(5):1924-1933.
144. Crosby WH. The metabolism of hemoglobin and bile pigment in hemolytic disease. Am J Med. 1955;18(1):112-122.
145. Bean CJ, et al. Heme oxygenase-1 gene promoter polymorphism is associated with reduced incidence of acute chest syndrome among children with sickle cell disease. Blood. 2012;120(18):3822-3828.
146. Ghosh S, et al. Nonhematopoietic Nrf2 dominantly impedes adult progression of sickle cell anemia in mice. JCI Insight. 2016;1(4):e81090.
147. Doss JF, Jonassaint JC, Garrett ME, Ashley-Koch AE, Telen MJ, Chi JT. Phase 1 study of a sulforaphane-containing broccoli sprout homogenate for sickle cell disease. PLoS One. 2016;11(4):e0152895.
148. Machado RF, et al. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood. 2011;118(4):855-864.
149. Gladwin MT, et al. Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br J Haematol. 2002;116(2):436-444.
150. Gladwin MT, Kania T, Kim-Shapiro DB. Hemolysis and cell-free hemoglobin drive an intrinsic mechanism for human disease. J Clin Invest. 2012;122(4):1205-1208.
151. Darbari DS, et al. Markers of severe vaso-occlusive painful episode frequency in children and adolescents with sickle cell anemia. J Pediatr. 2012;160(2):286-290.
152. Gill FM, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood. 1995;86(2):776-783.
153. Cumming V, King L, Fraser R, Serjeant G, Reid M. Venous incompetence, poverty and lactate dehydrogenase in Jamaica are important predictors of leg ulceration in sickle cell anaemia. Br J Haematol. 2008;142(1):119-125.
154. Koshy M, et al. Leg ulcers in patients with sickle cell disease. Blood. 1989;74(4):1403-1408.
155. Milner PF, et al. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med. 1991;325(21):1476-1481.
156. Powars DR, Chan L, Schroeder WA. The influence of fetal hemoglobin on the clinical expression of sickle cell anemia. Ann N Y Acad Sci. 1989;565:262-278.
157. Hawker H, Neilson H, Hayes RJ, Serjeant GR. Haematological factors associated with avascular necrosis of the femoral head in homozygous sickle cell disease. Br J Haematol. 1982;50(1):29-34.
158. Mahadeo KM, et al. Increased prevalence of osteonecrosis of the femoral head in children and adolescents with sickle-cell disease. Am J Hematol. 2011;86(9):806-808.
159. Diop S, et al. [Predictive factors of chronic complications in adult sickle cell anemia patients in Dakar, Senegal] (article in French). Med Trop (Mars). 2010;70(5-6):471-474.
160. Mukisi-Mukaza M, et al. Prevalence, clinical features, and risk factors of osteonecrosis of the femoral head among adults with sickle cell disease. Orthopedics. 2000;23(4):357-363.
161. Adekile AD. Limitations of Hb F as a phenotypic modifier in sickle cell disease: study of Kuwaiti Arab patients. Hemoglobin. 2011;35(5-6):607-617.
162. Emond AM, Holman R, Hayes RJ, Serjeant GR. Priapism and impotence in homozygous sickle cell disease. Arch Intern Med. 1980;140(11):1434-1437.
163. Nebor D, et al. Thalassemia is associated with a decreased occurrence and a delayed age-at-onset of albuminuria in sickle cell anemia patients. Blood Cells Mol Dis. 2010;45(2):154-158.
164. Haymann JP, et al. Glomerular hyperfiltration in adult sickle cell anemia: a frequent hemolysis associated feature. Clin J Am Soc Nephrol. 2010;5(5):756-761.
165. Ware RE, et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. J Pediatr. 2010;156(1):66-70.e1.
166. Powars DR, et al. Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality. Ann Intern Med. 1991;115(8):614-620.
167. Wigfall DR, Ware RE, Burchinal MR, Kinney TR, Foreman JW. Prevalence and clinical correlates of glomerulopathy in children with sickle cell disease. J Pediatr. 2000;136(6):749-753.
168. Becton LJ, et al. Prevalence and clinical correlates of microalbuminuria in children with sickle cell disease. Pediatr Nephrol. 2010;25(8):1505-1511.
169. King L, MooSang M, Miller M, Reid M. Prevalence and predictors of microalbuminuria in Jamaican children with sickle cell disease. Arch Dis Child. 2011;96(12):1135-1139.
170. Joly P, et al. G6PD deficiency and absence of thalassemia increase the risk for cerebral vasculopathy in children with sickle cell anemia. Eur J Haematol. 2016;96(4):404-408.
171. Belisário AR, et al. Association of alpha-thalassemia, TNF-α (-308G>A) and VCAM-1 (c.1238G>C) gene polymorphisms with cerebrovascular disease in a newborn cohort of 411 children with sickle cell anemia. Blood Cells Mol Dis. 2015;54(1):44-50.
172. Cox SE, et al. Haptoglobin, alpha-thalassaemia and glucose-6-phosphate dehydrogenase polymorphisms and risk of abnormal transcranial Doppler among patients with sickle cell anaemia in Tanzania. Br J Haematol. 2014;165(5):699-706.
173. Ohene-Frempong K, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91(1):288-294.
174. Kinney TR, et al. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. The Cooperative Study of Sickle Cell Disease. Pediatrics. 1999;103(3):640-645.
175. Kwiatkowski JL, et al. Silent infarcts in young children with sickle cell disease. Br J Haematol. 2009;146(3):300-305.
176. Hsu LL, et al. Thalassemia is associated with decreased risk of abnormal transcranial Doppler ultrasonography in children with sickle cell anemia. J Pediatr Hematol Oncol. 2003;25(8):622-628.
177. Wang WC, et al. MRI abnormalities of the brain in one-year-old children with sickle cell anemia. Pediatr Blood Cancer. 2008;51(5):643-646.
178. Mikobi TM, et al. Correlation between the lactate dehydrogenase levels with laboratory variables in the clinical severity of sickle cell anemia in Congolese patients. PLoS One. 2015;10(5):e0123568.
179. Hamad Z, Aljedai A, Halwani R, AlSultan A. UGT1A1 promoter polymorphism associated with serum bilirubin level in Saudi patients with sickle cell disease. Ann Saudi Med. 2013;33(4):372-376.
180. Wali YA, et al. Splenic function in Omani children with sickle cell disease: correlation with severity index, hemoglobin phenotype, iron status, and alpha-thalassemia trait. Pediatr Hematol Oncol. 2002;19(7):491-500.
181. Vasavda N, et al. The linear effects of alpha-thalassaemia, the UGT1A1 and HMOX1 polymorphisms on cholelithiasis in sickle cell disease. Br J Haematol. 2007;138(2):263-270.
182. Webb DK, Darby JS, Dunn DT, Terry SI, Serjeant GR. Gall stones in Jamaican children with homozygous sickle cell disease. Arch Dis Child. 1989;64(5):693-696.
183. Fox PD, Higgs DR, Serjeant GR. Influence of thalassemia on the retinopathy of homozygous sickle-cell disease. Br J Ophthalmol. 1993;77(2):89-90.
184. Condon PI, Marsh RJ, Maude GH, Higgs DR, Weatherall DJ, Serjeant GR. Thalassemia and the macular vasculature in homozygous sickle cell disease. Br J Ophthalmol. 1983;67(11):779-781.
185. Talbot JF, Bird AC, Rabb LM, Maude GH, Serjeant GR. Sickle cell retinopathy in Jamaican children: a search for prognostic factors. Br J Ophthalmol. 1983;67(11):782-785.
186. Taylor JG, et al. Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell disease. Am J Hematol. 2008;83(1):6-14.
187. Gordeuk VR, et al. Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease. Blood. 2009;114(21):4639-4644.
188. Barbedo MM, McCurdy PR. Red cell life span in sickle cell trait. Acta Haematol. 1974;51(6):339-343.
189. Mears JG, Lachman HM, Labie D, Nagel RL. Alpha-thalassemia is related to prolonged survival in sickle cell anemia. Blood. 1983;62(2):286-290.
190. Platt OS, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639-1644.